Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Masonic Cancer Center, University of Minnesota: Clinical Trials & FDA Approval Profile

Masonic Cancer Center, University of Minnesota (Global / Institutional) sponsors 35 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 15 active protocols (13 recruiting now), 11 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)25.7%
Median Closed Enrollment vs National (145 pts)16 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Masonic Cancer Center, University of Minnesota
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)35
Active Pipeline (Recruiting Now)15 (13)
Completed vs Stopped Early11 / 9 (25.7%)
Median Closed Actual Enrollment16 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Masonic Cancer Center, University of Minnesota
Hospital Research SiteLocationShared Protocols
University of Minnesota/Masonic Cancer CenterMinneapolis, MN5
University of MinnesotaMinneapolis, MN3

Explore interactive annual charts and M&A subsidiary rollups in the Masonic Cancer Center, University of Minnesota Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI